$2.05
+0.00 (+0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ACRV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 6 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, +1 more) · FINRA short interest 4.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaNCT05548296Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: ACR-368, Gemcitabine · Diagnostic test: OncoSignature | Endometrial Adenocarcinoma | 350 | 2027-05-30 | in 284 d | 2026-06-15 |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid TumorsNCT06667141Dose EscalationNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ACR-2316 | Specific Advanced Solid Tumors | 100 | 2026-08-12 | — | 2026-03-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19